Substitute for form 1449A/PTO & 1449B/PTO
SECOND
INFORMATION DISOLD&URE
STATEMENT BY APPLICANT
JUL 2 4 2006
Sheet 1 of

Complete if Known				
Application Number	10/641,149	<u></u>		
Filing Date	August 15, 2003			
First Named Inventor	Allan J. TOBIN et al.			
Examiner Name	Gabriele E. Bugaisky			
Confirmation No.	9827			
Group Art Unit	1656			
Attorney Docket Number	704611-3001			

U.S. PATENT DOCUMENTS					
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)	
		I			

		F	OREIGN PATENT DO	CUMENTS							
							ST	ATUS			
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
									-		┞
					l	<u> </u>	L	<u> </u>	L	Ц	<u></u>

	<u></u>
	NON-PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
Arc	T.A. M.A. Al-Bukhari et al., "Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutmamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis," 130 CLIN. EXP. IMMUNOL. 131-139 (2002).
W	J-M. Bach et al., "High Affinity Presentation of an Autoantigenic Peptide in Type I Diabetes by an HLA Class II Protein Encoded in a Haplotype Protecting From Disease," 10 JOURNAL OF AUTOIMMUNITY 375-386 (1997).
	A. Falorni et al., in "Diagnostic sensitivity of immunodominant epitopes of glutamic acid decarboxylase (GAD65) autoantibodies in childhood IDDM," 39 DIABETOLOGIA 1091-1098 (1996).
V	E. Harfouch-Hammoud et al., in "Identification of Peptides From Autoentigens GAD65 and IA-2 That Bind to HLA Class II Molecules Predisposing to or Protecting From Type 1 Diabetes," 48 DIABETES 1937-1947 (Oct. 1999).
J.R	D. Kaufman et al., "Autoimmunity to Two Forms of Glutamate Decarboxylase in Insulin-dependent Diabetes Mellitus," 89 J. CLIN. INVEST. 283-292 (Jan. 1992).
1	T. Kobayashi et al., in "Unique Epitopes of Glutamic Acid Decarboxylase Autoantibodies in Slowly Progressive Type 1 Diabetes," 88(10) The Journal of Clinical Endocrinology & Metabolism 4768-4775 (2003).
10	L. Li et al., "Differential Detection of Rat Islet and Brain Glutamic Acid Decarboxylase (GAD) Isoforms with Sequence- specific Peptide Antibodies," 43(1) The Journal of Histochemistry and Cytochemistry 53-59 (1995).
4	T. Lohmann et al., "Humoral and Cellular Autoimmune Responses in Stiff person Syndrome," 998 Ann. N.Y. Acad. Sci. 998 215-222 (2003).
	T. Lohmann et al., "Immunodominant epitopes of glutamic acid decarboxylase 65 and 67 in insulin-dependent diabetes mellitus," 343 THE LANCET 1607-1608 (June 25, 1994).
	T. Lohmann et al., "T cell Clones to Epitopes of Glutamic Acid Decarboxylase 65 Raised from Normal Subjects and Patients with Insulin-dependent Diabetes," 9 JOURNAL OF AUTOIMMUNITY 385-389 (1996).
W	M. A. Myers et al., "A Diabetes-Related Epitope of GAD65: A Major Diabetes-Related Conformational Epitope on GAD65," 1005 Annals of the New York Academy of Sciences 250-252 (2003).
THE STATE OF THE S	P. Panina-Bordignon et al., "Cytotoxic T Cells Specific For Glutamic Acid Decarboxylase in Autoimmune Diabetes," J. Exp. Med. 1923-1927 (May 1995).
	Salil D. Patel et al. in "Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR (01*0101,β1*0401) transgenic mice," 94 PRoc. NATL. Acad. Sci. USA 8082-87 (July 1997).
V	A. C. Powers et al., "Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders," 118 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 349-356 (1999).
Examiner	Date Gla Date

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

CCDCCS/660769.1

Substitute for form 144	9A/PTO & 14	449B/PTO		Complete if Known		
	S	ECON)	Application Number	10/641,149 .	
INFO	_		SCLOSURE	Filing Date	August 15, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Allan J. TOBIN et al.	
• • • • • • • • • • • • • • • • • • • •				Examiner Name	Gabriele E. Bugaisky	
				Confirmation No.	9827	
		Group Art Unit	1656			
Sheet	2	of	2	Attorney Docket Number	704611-3001	

	NON-PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
de	Anthony Quinn & Eli E. Sercarz, "T Cells with Multiple Fine Specificities are Used by Non-obese Diabetic (NOD) Mice in the Response to GAD(524-543)," 9 JOURNAL OF AUTOIMMUNITY 365-370 (1996).
	F. Rharbaoui et al., in "Peptide specificity of high-titer anti-glutamic acid decarboxylase (GAD)65 autoantibodies," 62
1/1/	Y. Shi et al., "Amino Acid Residues 24-31 but not Palmitoylation of Cysteines 30 and 45 Are Required for Membrane Anchoring of Glutamic Acid Decarboxylase, GAD₅₅," 124(6) The JOURNAL OF CELL BIOLOGY 927-934 (March 1994).
1/	M. Solimena et al., "A Signal Located within Amino Acids 1-27 of GAD65 Is Required for Its Targeting to the Golgi Complex Region," 126(2) The Journal of Cell Biology 331-341 (July 1994).
AR	K. Syren et al., "Immune Reactivity of Diabetes-Associated Human Monoclonal Autoantibodies Defines Multiple Epitopes
ر ما ر	M. A. Zechel et al., in "Characterization of Novel T-cell Epitopes on 65 kDa and 67 kDa Glutamic Acid Decarboxylase Relevant in Autoimmune Responses in NOD Mice," 11 JOURNAL OF AUTOIMMUNITY 83-95 (1998).

Examiner
Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DCDOCS/660769.1

DRAFT